These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 32341582)

  • 1. The Efficacy of Software to Help Patients Understand Drug for Adjuvant Treatment for Breast Cancer: A Pilot Randomized Controlled Trial.
    Kuba S; Yamanouchi K; Morita M; Sakimura C; Inamasu E; Hatachi T; Otsubo R; Matsumoto M; Yano H; Miyamoto J; Sato S; Nakagawa H; Kanetaka K; Takatsuki M; Nagayasu T; Eguchi S
    Acta Med Okayama; 2020 Apr; 74(2):95-101. PubMed ID: 32341582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cancer: A multicenter, open-label, randomized phase 2 study.
    Kuba S; Moriuchi H; Yamanouchi K; Shibata K; Yano H; Oikawa M; Maeda S; Meng X; Morita M; Hatachi T; Otsubo R; Matsumoto M; Miyamoto J; Kanetaka K; Taniguchi H; Nagayasu T; Eguchi S
    Contemp Clin Trials Commun; 2021 Mar; 21():100739. PubMed ID: 33718655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer.
    Partridge AH; Sepucha K; O'Neill A; Miller KD; Motley C; Swaby RF; Schneider BP; Dang CT; Northfelt DW; Sledge GW
    JAMA Oncol; 2015 Jun; 1(3):369-74. PubMed ID: 26114161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.
    Oestreicher N; Ramsey SD; McCune JS; Linden HM; Veenstra DL
    Cancer; 2005 Nov; 104(10):2054-62. PubMed ID: 16216002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
    Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
    Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer.
    Irwin E; Arnold A; Whelan TJ; Reyno LM; Cranton P
    Patient Educ Couns; 1999 Jul; 37(3):283-91. PubMed ID: 14528554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France.
    Laas E; Vataire AL; Aballea S; Valentine W; Gligorov J; Chereau E; Rouzier R
    J Med Econ; 2012; 15(6):1167-75. PubMed ID: 22853442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance).
    Gajra A; McCall L; Muss HB; Cohen HJ; Jatoi A; Ballman KV; Partridge AH; Sutton L; Parker BA; Magrinat G; Klepin HD; Lafky JM; Hurria A
    J Geriatr Oncol; 2018 May; 9(3):221-227. PubMed ID: 29602735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
    Colleoni M; Luo W; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Hitre E; Graas MP; Simoncini E; Kamby C; Thompson A; Loibl S; Gavilá J; Kuroi K; Marth C; Müller B; O'Reilly S; Di Lauro V; Gombos A; Ruhstaller T; Burstein H; Ribi K; Bernhard J; Viale G; Maibach R; Rabaglio-Poretti M; Gelber RD; Coates AS; Di Leo A; Regan MM; Goldhirsch A;
    Lancet Oncol; 2018 Jan; 19(1):127-138. PubMed ID: 29158011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer.
    Duric VM; Butow PN; Sharpe L; Boyle F; Beith J; Wilcken NR; Heritier S; Coates AS; John Simes R; Stockler MR
    Psychooncology; 2007 Jan; 16(1):48-59. PubMed ID: 16856128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II.
    Schwentner L; Van Ewijk R; Kühn T; Flock F; Felberbaum R; Blettner M; Kreienberg R; Janni W; Wöckel A; Singer S
    Support Care Cancer; 2016 Jun; 24(6):2759-66. PubMed ID: 26816089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of Pythagorean Self-Awareness Intervention on breast cancer patients undergoing adjuvant therapy: A pilot randomized controlled trial.
    Charalampopoulou M; Bacopoulou F; Syrigos KN; Filopoulos E; Chrousos GP; Darviri C
    Breast; 2020 Feb; 49():210-218. PubMed ID: 31901782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer.
    Barlow WE; Taplin SH; Yoshida CK; Buist DS; Seger D; Brown M
    J Natl Cancer Inst; 2001 Mar; 93(6):447-55. PubMed ID: 11259470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.